Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2 Revolutionary Stocks That Turned $200,000 Into $1,000,000

Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.

Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?

The stock price of Moderna Inc (NASDAQ: MRNA) increased from $178.82 to a day high of $188.88 (up 5.63%) during intraday trading this morning. This is why it happened.

MRNA Stock: From $178.82 To $188.88 (5.63% Increase) Explanation

Covax, the World Health Organization's vaccine sharing program, is in dire need of vaccine doses. Wealthier countries have faced calls to step up.

Moderna Pledges 500 Million Vaccine Doses To Stumbling WHO Program

Moderna Inc (NASDAQ: MRNA) has announced an agreement with vaccine promoter Gavi to supply up to 500 million doses of its COVID-19 vaccine to boost the global vaccination effort. Still, most of the shipments won't arrive until next year.

Moderna Inks Supply Pact Of 500M COVID-19 Vaccine Doses To COVAX Effort Starting Q4

Moderna Inc. announced Monday an agreement with the Vaccine Alliance, Gave, to supply up to 500 million doses of its COVID-19 vaccine on behalf of the COVAX Facility. The agreement covers the 92 Gavi COVAX Advance Market Commitment for low- and middle-income countries.

Moderna to supply 500 million COVID-19 vaccine doses on behalf of COVAX

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces supply agreement with Gavi for up to 500 million doses of COVID-19 vaccine for COVAX to help end pandemic in lowest income countries

Moderna Announces Supply Agreement with Gavi for up to 500 Million Doses of COVID-19 Vaccine Moderna for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

They'll give us a snapshot of the future.

The 2 Numbers I'll Be Looking for in Moderna's Earnings Report This Week

Pfizer

BioNTech SE

Both vaccines do an impressive job of providing protection against COVID-19. But Moderna's is much easier to get from production facilities into patients' arms.

Moderna Just Made the Pfizer Vaccine's Biggest Weakness an Even Bigger One

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces Emergency Use Listing granted by the World Health Organization for its COVID-19 vaccine.

Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine

Loncar China Biopharma ETF

Loncar Cancer Immunotherapy ETF

CRISPR Therapeutics

CureVac B.V

Editas Medicine

iShares Nasdaq Biotechnology ETF

Telesis Bio Inc

SPDR S&P Biotech ETF

Here is what you should know about investing in these life changing technologies.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Apple

Amazon

Costco

Netflix

PepsiCo

Kraft Heinz

Marriott

Starbucks

Blue-chip stocks are well-known companies with a history of growth and dividend payments. Here are seven to buy from Nasdaq.

10 of the Top Nasdaq Blue-Chip Stocks to Buy

The U.S. biotech also announced that its Covid-19 vaccine can be stored for up to three months at a refrigerator temperature of 2 to 8 Celsius.

Moderna in Bid to Double Covid-19 Vaccine Production to up to 3 Billion Doses in 2022.

The U.S. biotech also raised its manufacturing forecast for 2021 to 800 million to 1 billion doses.

Moderna in bid to double COVID-19 vaccine production to up to 3 billion doses in 2022

Moderna Inc (NASDAQ: MRNA) plans to produce up to 3 billion doses in 2022, doubling capacity at contract sites in Switzerland and Spain run by Lonza Group (OTCMKTS: LZAGF) and Rovi, respectively, and increasing drug substance manufacturing by 50% at its U.S. facilities. The expansions will also allow Moderna to now produce between 800 million and 1 billion doses in 2021, the company said.

Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually

Moderna Inc (NASDAQ:MRNA) announced it is making new funding commitments to increase global capacity to up to 3bn COVID-19 vaccine doses in 2022. The biotech also raised its 2021 supply forecast to 800mln-1bn doses.

Moderna boosts investments to reach 3bn doses capacity in 2022

AbbVie

Amgen

Bristol-Myers

Johnson & Johnson

SoFi Select 500 ETF

High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now.

7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends

It might be a sign that even bigger deals are on the way.

Why Moderna's Latest Supply Deal Could Make the Stock a Big Bargain Right Now

Moderna's Covid-19 vaccine can remain stable at temperatures found in refrigerators for 3 months, the company said Thursday, citing new data.

Moderna Covid vaccine can remain stable at refrigerated temperatures for 3 months, company says

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces additional investments to increase global supply for COVID-19 Vaccine to up to 3 billion doses in 2022.

Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022

Moderna is anticipating a "significant need" for its COVID-19 vaccine through 2022 and 2023, leading the biotech firm to ramp up production efforts, the company said early Thursday. Moderna is aiming to manufacture up to 3 billion doses in 2022, the Cambridge, Massachusetts-based company said in a statement, up from as many as 1 billion this year.

Moderna plans to produce up to 3 billion COVID-19 vaccine doses next year, citing a 'significant need' for shots and boosters into 2023

The two-dose vaccines were also found to be 64% effective at preventing hospitalizations in the elderly who received just one shot, according to the CDC study.

Pfizer, Moderna vaccines 94% effective at preventing hospitalizations in elderly, CDC study shows

Adults of 65 years and older are 94% less likely to be hospitalized with COVID-19 if they have been fully vaccinated with either of the two mRNA vaccines that have received emergency use authorization in the U.S., compared with people of the same age who are not vaccinated, the Centers for Disease Control and Prevention said Wednesday. People who are partially vaccinated with those vaccines -- one developed by Pfizer Inc. and German partner BioNTech SE , and one developed by Moderna Inc. -- are 64% less likely to be hospitalized compared with people who are not vaccinated, the agency said.

Older adults 94% less likely to be hospitalized with COVID after receiving Pfizer or Moderna vaccines: CDC

Moderna Inc (NASDAQ: MRNA) said that the U.S. government had agreed to increase the contract for the company's COVID-19 vaccine by $236 million to roughly $1.25 billion to include additional costs related to the shot's studies, according to SEC filing. The latest funds will reimburse for Moderna's costs associated with the vaccine's Phase III clinical trial, as well as pharmacovigilance efforts to track the vaccine's safety.

U.S. Government Bolsters Moderna COVID-19 Vaccine Contract To $1.25B

ASML Hld

Green Thumb Industries Inc.

Each of these three companies is on the precipice of decade-long growth.

News for Moderna Stock (MRNA)